Cosunter's 7th Scholarship and Sponsorship Award Ceremony (SSAC 2017) Successfully Held in Ningde
Cosunter's SSAC themed “Cheer You on for Sailing Your Dreams” came to a successful end at Zherong No.1 High School of Ningde, Fujian, on August 15.
Fujian Cosunter Pharmaceutical Co., Ltd. Obtains Approval for Setup of Academician Expert Workstation
The Academician Expert Workstation of Fujian Cosunter Pharmaceutical Co., Ltd. has been honored with the title"Fujian Provincial Academician Expert Workstation",becoming one of the 23 newly established provincial academician expert workstations across Fujian.
Listing Conference of FGD for CHB Indications -“Fuganding® TDF” Held in Beijing
Approval of TDF bulk drug and capsules in May, 2017 helps Cosunter become the only enterprise to have the two priority anti-HBV medicines of TDF and ETV, with the most complete production line in the anti-HBV field in China.
Cosunter Obtains 1st Approval for Production of TDF for HBV Indications
On May 18, the important medicine of Fujian Cosunter Pharmaceutical Co., Ltd., “Fuganding-Tenofovir Disoproxil Fumarate Capsules (Approval No.:SFDA 2017H0005) is successfully approved.
Disclosure of Cosunter’s Environmental Influence Assessment Report for Its Synthetic Drug Technology Renovation Project
Cosunter has engaged an EIA institution to prepare the Environmental Influence Assessment Report for Cosunter’s Synthetic Drug Technology Renovation Project.
Strategic Cooperation Agreement signed by Cosunter and Sinopharm Group
Both parties hope to share all strategic resources by intercommunication on the basis of separated purchasing negotiated and relying on third-party logistics and multiple-warehouse operation for the win-win purpose.
Clinical Data Collected over Three Years from TDF-ETV Non-inferiority Control Trial by Cosunter First Released Globally at APASL Annual Meeting 2017
The 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) was held at Shanghai International Convention Center on February 15 - 19, 2017 in Shanghai, China.
Strategic Cooperation Framework Agreement Signed by Cosunter and WuXi AppTec for “the Best Plan of HBV Treatment”
Cosunter cooperated with WuXi AppTec regarding the project related to HBV treatment method independently developed by Cosunter for the purpose of “the Best Plan of HBV Treatment”. The Strategic Cooperation Framework Agreement was signed by both parties on February 9, 2017.
Cosunter’s Annual Meeting Themed “Transformation to a New Stage in 2017” Held in Fuzhou
Time flies and a busy year - 2016 has passed but an expectant new year - 2017 is saying hi to us. A new year means new target and new hope. Fujian Cosunter Pharmaceutical Co., Ltd. held its annual meeting themed “transformation to a new stage in 2017” in Fuzhou from January 22 to 23, 2017. All staff members were excited to witness and share these warm and impressive moments during the meeting.
Second Disclosure of Cosunter’s Environmental Influence Assessment for Its Synthetic Drug Technology Renovation Project
Cosunter has engaged an EIA institution to prepare the Environmental Influence Assessment Report for Cosunter’s Synthetic Drug Technology Renovation Project (simplified edition). We disclose the preliminary conclusion of this EIA for the project to the public according to the Law of the People's Republic of China on Appraising of Environment and the Temporary Methods of Public Consultation for EIA.